See more : Yorkey Optical International (Cayman) Ltd. (2788.HK) Income Statement Analysis – Financial Results
Complete financial analysis of L&C Bio Co., Ltd (290650.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of L&C Bio Co., Ltd, a leading company in the Medical – Specialties industry within the Healthcare sector.
- Petrotech Oil and Gas, Inc. (PTOG) Income Statement Analysis – Financial Results
- Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ) Income Statement Analysis – Financial Results
- Constellation Software Inc. (CNSWF) Income Statement Analysis – Financial Results
- Growth Capital Acquisition Corp. (GCACW) Income Statement Analysis – Financial Results
- Planet Green Holdings Corp. (PLAG) Income Statement Analysis – Financial Results
L&C Bio Co., Ltd (290650.KQ)
About L&C Bio Co., Ltd
L&C BIO Co., Ltd. operates as a research and development company in tissue regeneration medicine. It offers human tissue, medical device, and cosmetics products. The company was founded in 2011 and is headquartered in Seongnam, South Korea.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 68.87B | 52.57B | 45.68B | 32.97B | 29.15B | 21.24B | 17.90B | 11.82B | 9.00B |
Cost of Revenue | 36.34B | 25.58B | 17.23B | 13.41B | 10.49B | 7.86B | 6.76B | 4.83B | 4.69B |
Gross Profit | 32.53B | 26.99B | 28.45B | 19.56B | 18.66B | 13.38B | 11.14B | 6.99B | 4.31B |
Gross Profit Ratio | 47.23% | 51.34% | 62.29% | 59.32% | 64.02% | 63.00% | 62.21% | 59.12% | 47.87% |
Research & Development | 3.84B | 2.20B | 2.29B | 2.38B | 1.35B | 1.27B | 917.87M | 944.28M | 359.45M |
General & Administrative | 3.09B | 1.90B | 1.73B | 2.03B | 1.40B | 1.02B | 969.77M | 866.61M | 580.59M |
Selling & Marketing | 11.20B | 7.52B | 6.83B | 5.20B | 4.30B | 3.74B | 2.70B | 1.76B | 1.05B |
SG&A | 20.94B | 9.42B | 8.55B | 7.23B | 5.70B | 4.76B | 3.67B | 2.62B | 1.63B |
Other Expenses | 0.00 | 232.32M | 302.66M | 22.30M | 56.57M | 16.56M | -6.58M | 337.85M | 150.47M |
Operating Expenses | 27.02B | 17.51B | 15.28B | 12.23B | 9.63B | 7.90B | 6.26B | 4.92B | 3.19B |
Cost & Expenses | 61.12B | 43.09B | 32.51B | 25.65B | 20.12B | 15.76B | 13.03B | 9.75B | 7.88B |
Interest Income | 1.53B | 562.55M | 363.47M | 609.74M | 913.71M | 227.11M | 86.17M | 8.90M | 4.19M |
Interest Expense | 6.19B | 3.08B | 460.27M | 743.24M | 60.55M | 18.05M | 319.11M | 335.17M | 145.00M |
Depreciation & Amortization | 5.65B | 5.80B | 2.90B | 1.59B | 1.09B | 481.83M | 295.38M | 286.53M | 233.45M |
EBITDA | 13.40B | 14.25B | 16.07B | 8.91B | 10.12B | 6.39B | 5.17B | 2.83B | 1.66B |
EBITDA Ratio | 19.46% | 26.27% | 44.86% | 45.91% | 38.00% | 29.20% | 29.21% | 22.85% | 16.84% |
Operating Income | 7.75B | 9.48B | 13.17B | 7.32B | 9.03B | 5.48B | 4.87B | 2.07B | 1.12B |
Operating Income Ratio | 11.25% | 18.04% | 28.83% | 22.21% | 30.98% | 25.79% | 27.21% | 17.54% | 12.48% |
Total Other Income/Expenses | 55.19B | -4.92B | 3.93B | 5.62B | 889.41M | 413.54M | -342.93M | 134.94M | 156.56M |
Income Before Tax | 62.94B | 4.56B | 17.10B | 12.94B | 9.92B | 5.89B | 4.61B | 2.21B | 1.28B |
Income Before Tax Ratio | 91.39% | 8.68% | 37.43% | 39.26% | 34.03% | 27.73% | 25.77% | 18.68% | 14.22% |
Income Tax Expense | 14.41B | -1.13B | 1.51B | 795.51M | 1.47B | 796.46M | 859.71M | 226.90M | 77.51M |
Net Income | 48.36B | 4.54B | 13.81B | 10.81B | 7.25B | 5.21B | 3.75B | 1.98B | 1.20B |
Net Income Ratio | 70.22% | 8.64% | 30.24% | 32.79% | 24.87% | 24.52% | 20.97% | 16.76% | 13.36% |
EPS | 2.10K | 200.32 | 619.55 | 493.83 | 331.03 | 276.67 | 469.33 | 258.33 | 159.00 |
EPS Diluted | 1.96K | 200.32 | 619.55 | 493.83 | 330.03 | 271.00 | 469.33 | 258.33 | 159.00 |
Weighted Avg Shares Out | 23.07M | 22.68M | 22.30M | 21.90M | 21.90M | 18.82M | 7.99M | 7.67M | 7.56M |
Weighted Avg Shares Out (Dil) | 24.72M | 22.68M | 22.30M | 21.90M | 21.97M | 19.22M | 8.00M | 7.67M | 7.56M |
Source: https://incomestatements.info
Category: Stock Reports